Taxol News and Research

RSS
Taxol is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Taxol is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called paclitaxel.
AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium

AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium

E. coli host bacterium produces antibiotic erythromycin A

E. coli host bacterium produces antibiotic erythromycin A

Cell Therapeutics announces preliminary results of phase II OPAXIO study for high-grade gliomas

Cell Therapeutics announces preliminary results of phase II OPAXIO study for high-grade gliomas

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Study demonstrates potent anticancer properties of quinoxalinyl-piperazine compounds

Study demonstrates potent anticancer properties of quinoxalinyl-piperazine compounds

Genta commences tesetaxel Phase 2b clinical trial as 1st-line chemotherapy for metastatic breast cancer

Genta commences tesetaxel Phase 2b clinical trial as 1st-line chemotherapy for metastatic breast cancer

FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer

FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer

Rexahn announces publication of 3-aryl-1-isoquinolinamines preclinical data

Rexahn announces publication of 3-aryl-1-isoquinolinamines preclinical data

Study suggests epoD; microtubule-stabilizing drugs may treat neurodegenerative diseases

Study suggests epoD; microtubule-stabilizing drugs may treat neurodegenerative diseases

NCCN updates Clinical Practice Guidelines for Breast Cancer

NCCN updates Clinical Practice Guidelines for Breast Cancer

AVEO presents tivozanib Phase 2 study results at ESMO Congress

AVEO presents tivozanib Phase 2 study results at ESMO Congress

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer

FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

Elsevier Properties congratulates Stewart for achieving Lectureship

Elsevier Properties congratulates Stewart for achieving Lectureship

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO